Mark Yarchoan
Bloomberg (United States)(US)Johns Hopkins University(US)Johns Hopkins Medicine(US)Sidney Kimmel Cancer Center(US)Sidney Kimmel Comprehensive Cancer Center(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Hepatocellular Carcinoma Treatment and Prognosis, Immunotherapy and Immune Responses, Cholangiocarcinoma and Gallbladder Cancer Studies
Most-Cited Works
- → Tumor Mutational Burden and Response Rate to PD-1 Inhibition(2017)3,270 cited
- → Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic(2018)2,846 cited
- → AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma(2023)1,480 cited
- → Targeting neoantigens to augment antitumour immunity(2017)1,020 cited
- → PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers(2019)530 cited
- → Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity(2021)333 cited